The efficacy of angiotensin II receptors’ blockers use in patients wkth arterial hypertension and metabolic syndrome


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Article contains the results of effective use of a new sartanes representative of arterial hypertension in combination with metabolic syndrome. research works it induced the increase of glucose tolerance and insulin sensitivity, increase of PPAR-Yand adiponectin expression, inhibited albuminuria and proteinuria progression, supressed vessel wall cells proliferation.

全文:

受限制的访问

作者简介

Anna Evdokimova

A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia

Email: Aevdokimova@rambler.ru
MD, professor of the Department of hospital therapy № 2

Yelena Kovalenko

A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia

PhD, associate professor of the Department of hospital therapy № 2

Vladimir Evdokimov

A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia

PhD, associate professor of the Department of hospital therapy № 2

Konstantin Tebloev

A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia

MD, professor, head of the Department of hospital therapy № 2

参考

  1. Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваск. терапия и профилакт. 2014; 13(6): 4-11.
  2. Клинические рекомендации «Диагностика и лечение артериальной гипертензии» Российского медицинского общества по артериальной гипертонии, 2013. Кардиологическийвестник. 2015; 10(1).
  3. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический Вестник. 2014; 1: 4-57.
  4. Xie X., Atkins E., Lv J.,Bennett A., Neal B., Ninomiya T., Woodward M., MacMahon S., Turnbull F., Hillis G.S., Chalmers J., Mant J., Salam A., Rahimi K., Perkovic V., Rodgers A. Effects of intensive Itlood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387(10017): 435-43.
  5. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 2003; 11: 1278-89.
  6. Rabmouni K., Correia M.L.G., Haynes W.G., Mark A.L. Obesity -associated Hypertension. New insights into mechanisms. Hypertension. 2005; 45: 9-14.
  7. Carey R.M., Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 2003; 24(3): 261-71.
  8. Cheung B.M. The new cardiovascular continuum. Hong Kong Med. J.2006; 12(2): 161-3.
  9. Дедов И.И., Шестакова М.Н. Диабетическая нефропатия. М.: Универсум Паблишинг, 2000.240 с.
  10. Евдокимова А.Г., Рыжова Ю.В. Современные аспекты антигипертензивной терапии с позиций кардио- и нефропротективного воздействия. Антибиотики и химиотерапия. 2015; 5-6: 34-41.
  11. Matchar D.B., McCrory D.C., Orlando L.A.,Patel M.R., Patel U.D., Patwardhan M.B., Powers B., Samsa G.P., Gray R.N. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann. Intern. Med. 2008; 148: 16-29.
  12. Kobori H., Nangaku M., Navar L.G., Nishiyama A. The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. Pharmacol. Rev. 2007; 59(3): 251-87.
  13. Engeli S., Gorzelniak K., Kreutz R.,Runkel N., Distler A., Sharma A.M. Co-expression of reninangiotensin system genes in human adipose tissue. J. Hypertens. 1999; 1 7: 555-60.
  14. Кисляк О.А., Похильченко М.В. Дополнительные возможности антигипертензивной терапии при метаболическом синдроме. Системные гипертензии. 2013; 2: 41-6.
  15. Ferre P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004; 53: 43-50.
  16. Sample R.K., Krishna V., Chatterjee K., O'Rahilly S. PPARy and human metabolic disease. J. Clin. Invest. 2006; 116(3): 581-9.
  17. Kurtz T., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 2009; 32 (10): 826-34.
  18. Clasen R., Schupp M., Foryst-Ludwig A.,Sprang C., Clemenz M., Krikov M., Thöne-Reineke C., Unger T., Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005; 46(1): 137-43.
  19. Lindholm L., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 1004-10.
  20. Кобалава Ж.Д. Ранний, стабильный контроль АД - гарант улучшения прогноза при артериальной гипертонии высокого риска: результаты мегаисследования VALUE. РМЖ. 2004; 15.
  21. Julius S., Kjeldsen S.E., Weber M., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004; 363: 2022-31.
  22. Pfeffer M.A., Swedberg K., Grander C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., Pocock S.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003; 362: 759-66.
  23. Grander C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., Swedberg K.; CHARM Investigators and Committees.Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitоrs: the CHARM-Alternative trial. Lancet. 2003; 362: 772-6.
  24. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003; 362: 767-71.
  25. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARMPreserved trial. Lancet. 2003; 362: 777-81.
  26. Lindholm L.H., Persson M., Alaupovic P., Carlberg B. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. 2003; 21(8): 1563-74.
  27. Elliott W., Meyer P. Incidence diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201-7.
  28. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851-60.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##